Follow us on Twitter
twitter icon@FreshPatents


Hepatitis A patents

      

This page is updated frequently with new Hepatitis A-related patent applications.




 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Composition for preventing or treating fatty liver diseases patent thumbnailComposition for preventing or treating fatty liver diseases
The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating nafld, and in particular, nash..
Lg Life Sciences Ltd.


 Compositions and methods for detection of hepatitis a virus nucleic acid patent thumbnailCompositions and methods for detection of hepatitis a virus nucleic acid
Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of hav rna sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting hav nucleic acid sequences are disclosed..
Gen-probe Incorporated


 Immunogenic compositions for inhibiting hepatitis d virus patent thumbnailImmunogenic compositions for inhibiting hepatitis d virus
Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include nucleic acids encoding hepatitis b core antigen (hbcag) protein in combination with one or more self-cleavage 2a polypeptides and a second antigenic polypeptide.
Chrontech Pharma Ab


 Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation  same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases patent thumbnailIndanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis a, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media..
Katholieke Universiteit Leuven K.u. Leuven R & D


 Compositions and methods for treating non-alcoholic steatohepatitis patent thumbnailCompositions and methods for treating non-alcoholic steatohepatitis
Compositions and methods for the treatment of non-alcoholic steatohepatitis and related disorders are provided herein, for example in women under 50 or pre-menopausal women.. .
Mochida Pharmaceutical Co., Ltd.


 Sparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure patent thumbnailSparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure
The invention relates to the identification of secreted protein, acidic and rich in cysteine (sparc) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of sparc and/or interferes with its biological function..
Asociacion Civil De Estudios Superiores (aces)


 Treatment of herpes, pseudomonas, staph, and hepatitis patent thumbnailTreatment of herpes, pseudomonas, staph, and hepatitis
An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas, staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time.
Meritus Corporation


 Antagonists of cb1 receptor patent thumbnailAntagonists of cb1 receptor
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
Universite De Bordeaux


 Gene signatures of inflammatory disorders that relate to the liver patent thumbnailGene signatures of inflammatory disorders that relate to the liver
This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (crohn's and ulcerative colitis).
Institut National De La Recherche Agronomique


Method of producing therapeutic agent

The present invention relates to a therapeutic agent, wherein the therapeutic agent is d-boramine. The therapeutic agent is prepared by mixing l-carnitine tartrate, pyridoxal 5′ phosphate and fumaric acid.

Methods of treating liver diseases

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2..
Zafgen, Inc.

Selective detection of hepatitis a, b, c, d, or e viruses or combination thereof

Processes and compositions are provided for the detection of hepatitis viruses in a sample. Particular processes and compositions are provided for the selective detection of hdv.
The Usa, As Represented By The Secretary, Depart- Ment Of Health And Human Services

Novel fatty acids and their use in conjugation to biomolecules

Wherein r1, r2, r3, r4, ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as gdf15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Composition for preventing or treating inflammatory disease

A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease..
National University Corporation Nagoya University

Use of heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatitis and hepatoma

The present invention is directed to a use of a heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatitis by scavenging hepatitis b virus-infected cells. The heat shock protein inhibitor is selected from a group including ver-155008, pifithrin-μ, and pharmaceutical acceptable salts thereof.
National Tsing Hua University

Novel compound, pharmaceutically acceptable salt or optical isomer thereof, preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis a, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media..
Katholieke Universiteit Leuven K.u.leuven R & D

Compositions and methods that enhance an immune response

Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis b core antigen (hbcag) protein and a heterologous protein antigen.
Chrontech Pharma Ab

Methods of diagnosing liver cancer in a subject and a kit for diagnosing liver cancer

Disclosed are methods of diagnosing liver cancer in a subject as well as methods of assessing the risk of a subject having chronic hepatitis and liver cirrhosis of developing liver cancer. Also disclosed are kits for the diagnosis of liver cancer..
Singapore Health Services Pte Ltd

Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and/or salt thereof for improving liver functioning

A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Novel biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers

The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kda protein fragment consisting of amino acid sequence expressed by sequence no.
Mcbi, Inc.

Methods and compositions for diagnosis and prognosis of sepsis

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the invention relates to using assays that detect one or more of wap four-disulfide core domain protein 2, hepatitis a virus cellular receptor 1, interleukin-1 receptor-like 1, and proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic in such patients..
Astute Medical, Inc.

Urea compounds and their use as enzyme inhibitors

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

Method for diagnosing acute alcoholic hepatitis

Various methods for determining whether a subject has alcoholic hepatitis are described. In one aspect, a method for determining whether a subject has alcoholic hepatitis is described.
The Cleveland Clinic Foundation

Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses

Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis a virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus..

Compositions and methods for the treatment of inflammatory disorders

The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Compositions and methods for detection of hepatitis a virus nucleic acid

Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of hav rna sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting hav nucleic acid sequences are disclosed..
Gen-probe Incorporated

Modulation of tim receptor activity in combination with cytoreductive therapy

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved igv and mucin domains.
Children's Hospital Corporation

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis a, b, c and other types of hepatitis, the diseases and conditions caused by hiv or associated with hiv, including aids.. .

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis a, b, c and other types of hepatitis, the diseases and conditions caused by hiv or associated with hiv, including aids.. .

Compositions and methods for treating steatohepatitis, liver fibrosis, and hepatocellular carcinoma (hcc)

The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (hcc) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (il-17) and/or interleukin 23 (il-23) and/or signal transducer and activator of transcription 3 (stat3) and/or janus kinase 2 (jak2). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of a compound that increase the level of interleukin 22 (il-22) and/or interleukin 25 (il-25) and/or interleukin 27 (il-27).
The Regents Of The University Of California

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, pediarix® (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis b (recombinant) and inactivated poliovirus vaccine), havrix® (hepatitis a vaccine), engerix-b® (hepatitis b vaccine (recombinant)), twinrix® (hepatitis a & hepatitis b (recombinant) vaccine), eperzan® (albiglutide), mage-a3 antigen-specific cancer immunotherapeutic (astuprotimut-r), gsk2402968 (drisapersen), and hz/su (herpes zoster vaccine)..

Hepatitis virus culture systems using stem cell-derived human hepatocyte-like cells and their methods of use

The invention relates to the discovery that dhh derived from stem cells are permissive for infection by hepatitis viruses (hv), such as hepatitis a virus (hav), hepatitis b virus (hbv), hepatitis c virus (hcv), hepatitis d virus (hdv) and hepatitis e virus (hev). Included in the invention are hv-permissive dhhs and methods of making an hcv-permissive dhh derived from a stem cell.

Use of photosensitizer in preparation of virus-inactivating medicaments for treating diseases

The invention relates to the field of medicament use, in particular to the clinical use of photosensitizers for inactivating viruses in the treatment of blood vessel plaque, leukemia, aids, hepatitis and the like. The invention is based on the affinity of photosensitizer to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, to destroy focus cells or virus by generating singlet oxygen (1o2) under the effect of a method using laser, x-ray, ultrasound and medicament.

Compositions and detecting human parvovirus nucleic acid and for detecting hepatitis a virus nucleic acids in single-plex or multiplex assays

Nucleic acid oligomers specific for human parvovirus genomic dna are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed.

Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses

Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl α-ketoamides, peptidyl bisulfite salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis a virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus..

Antagonists of cb1 receptor

The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .

Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis

In various embodiments, the present invention provides methods of treating and/or preventing nash and/or pbc comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .

1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient

Disclosed are 1,3-dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis a, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media..

Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases

Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis a, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media..

Modified polynucleotides encoding hepatitis a virus cellular receptor 2

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmrna molecules.. .

Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof

The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.



Hepatitis A topics:
  • Hepatitis A
  • Steatohepatitis
  • Liver Disease
  • Hepatitis B
  • Alcoholic Fatty Liver
  • Fatty Liver
  • Nonalcoholic Steatohepatitis
  • Liver Fibrosis
  • Herpes Simplex
  • Hepatitis C
  • Tuberculosis
  • Chronic Hepatitis
  • Amino Acid Sequence
  • Amino Acid
  • Herpes Simplex Virus


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Hepatitis A for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hepatitis A with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4569

    file did exist - file did put2026

    3 - 1 - 43